Australia, New Zealand & Canada Pernicious Anaemia Information

In Australia and New Zealand, there are no standalone national guidelines dedicated solely to pernicious anaemia (PA) or vitamin B12 deficiency. Guidance is embedded in broader resources on anaemia, nutrition, and primary care, often aligning with international standards such as the British Committee for Standards in Haematology (BCSH) or UK NICE guidelines. Similar patterns exist in Canada. Below is a summary based on key professional and health authority resources.

Australia

1. Royal Australian College of General Practitioners (RACGP)
Guidance: The RACGP does not have a specific guideline for Pernicious Anemia or B12 deficiency but addresses these conditions in the context of anemia and nutritional deficiencies. A 2015 RACGP article on refugee health highlights the prevalence of B12 deficiency in certain populations and provides practical recommendations for screening and management.
Key Points:
Diagnosis: Diagnosis involves a full blood count (FBC) to identify megaloblastic anemia (macrocytosis, low hemoglobin) and serum B12 levels. If B12 levels are borderline (151–240 pmol/L), additional tests like holotranscobalamin (active B12) or methylmalonic acid (MMA) are recommended. Intrinsic factor antibodies (IFAB) are tested to confirm Pernicious Anemia, with positive results indicating a 95% likelihood of the condition.
Treatment:
For Pernicious Anemia, intramuscular (IM) hydroxocobalamin (1000 mcg, 3 times weekly for 2 weeks, then every 3 months lifelong) is the standard due to malabsorption.

2. Australian Prescriber 

Key Recommendations:

Diagnosis: Full Blood Count + serum B12 as first-line tests. Use MMA/active B12 for clarification. Intrinsic Factor Anti-Bodies positive in ~50% of PA cases but highly specific.

Causes: Pernicious Anemia is the most significant cause of B12 deficiency requiring lifelong treatment.

Treatment: IM hydroxocobalamin 1000 mcg for PA (loading then maintenance every 3 months). Lifelong IM replacement recommended for irreversible malabsorption.

3. myDr.com.au (2016, updated)

Key Points:
Diagnosis: Confirmed via FBC (showing megaloblastic anemia), serum B12 levels, and intrinsic factor/parietal cell antibody tests. Holotranscobalamin and MMA are used for unclear cases.

Treatment: Pernicious anemia requires lifelong IM B12 injections (hydroxocobalamin, typically 1000 mcg monthly after initial repletion).
Emphasizes the importance of lifelong treatment for pernicious anemia and monitoring for complications like gastric cancer.

4. Australian Clinical Labs (2024)
Key Recommendations:
Tests include total B12, holotranscobalamin (active B12), and MMA for borderline cases. Active B12 is automatically tested if total B12 is in the equivocal range (150–200 pmol/L).

Treatment regimens vary: 1000 mcg IM every few days to every few months, depending on severity and maintenance needs. 

Canada

In Canada, there are no standalone national guidelines dedicated exclusively to pernicious anemia or vitamin B12 deficiency from a single authoritative body like the Canadian Medical Association (CMA) or Health Canada. However, clinical guidance is provided through various professional organizations, medical societies, and regional health authorities, which align with international standards (e.g., British Committee for Standards in Haematology, U.S. recommendations, and UK NICE guidelines). These recommendations are embedded within broader frameworks for anemia, nutritional deficiencies, and autoimmune disorders. Below is a summary of the relevant guidance and clinical practices for Pernicious Anemia and vitamin B12 deficiency in Canada, based on available sources and clinical standards.

Note: The Active B12 test is available in only 5 provinces and as a referral to a hospital. Hydroxocobalamin is available but only through a compounding pharmacy and very rarely prescribed as it’s not covered by insurance.

1. British Columbia Guidelines (2023

• Routine screening in asymptomatic patients is not recommended.
• Consider supplementation without testing in high-risk asymptomatic individuals.
• Diagnosis: FBC + serum B12; MMA/active B12 for confirmation.
• Treatment: IM B12 (1000 mcg weekly for 4 weeks, then monthly) for deficiency; lifelong for PA/malabsorption. Oral high-dose possible for maintenance.

2. Canadian Medical Association / Family Physicians + Gastroenterology Societies (CSG/CAG)

Symptoms prompting screening include fatigue, neurological symptoms (numbness, tingling, cognitive changes), glossitis, or megaloblastic anemia on full blood count (FBC).

Diagnosis:
Initial tests include FBC (to detect megaloblastic anemia, characterized by macrocytosis and low hemoglobin) and serum B12 levels.
Serum B12 <150 pmol/L is diagnostic for deficiency. Borderline levels (150–250 pmol/L) require confirmatory testing with serum methylmalonic acid (MMA) or holotranscobalamin (active B12), as these are more sensitive.
For suspected pernicious anemia, test for anti-intrinsic factor antibodies (positive in ~50–70% of cases, highly specific) and, if available, anti-parietal cell antibodies (less specific). Elevated serum gastrin or low pepsinogen levels can support a diagnosis of autoimmune gastritis.

Treatment:
For pernicious anemia (due to intrinsic factor deficiency):
Intramuscular (IM) hydroxocobalamin or cyanocobalamin (1000 mcg daily or 3 times weekly for 2 weeks, then monthly lifelong) is the standard due to malabsorption.
If folate deficiency coexists, treat with both B12 and folate to avoid neurological worsening from B12 deficiency masked by folate supplementation.

Monitoring and Follow-Up:
Patients with pernicious anemia require lifelong B12 supplementation and periodic monitoring for response (FBC, B12 levels) and complications (e.g., gastric cancer risk due to autoimmune gastritis).
Patients with neurological symptoms may need more frequent initial injections (e.g., daily for 1–2 weeks) and longer recovery time (up to 6 months).
Additional: Upper endoscopy at diagnosis to assess for autoimmune gastritis and gastric neoplasia risk; ongoing surveillance recommended.

Note: Hydroxocobalamin availability can be limited (often compounded); cyanocobalamin is more common. Practices vary regionally.